MicroRNA-9 Enhanced Cisplatin Sensitivity in Nonsmall Cell Lung Cancer Cells by Regulating Eukaryotic Translation Initiation Factor 5A2

• Published in: BioMed research international 2018-01, Vol.2018 (2018), p.1-8
• Main Authors: Xu, Guodong, Song, Jie, Shi, Huoshun, Li, Ni, Zheng, Dawei, Sun, Lebo, Pan, Qiaoling, Shao, Guofeng
• Format: Article
• Language: English
• Subjects: Antineoplastic Agents - therapeutic use; Apoptosis; Bioinformatics; Biomarkers; Biotechnology; Breast cancer; Cancer; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Cell growth; Cell Line, Tumor; Cell proliferation; Chemoresistance; Chemotherapy; Cisplatin; Cisplatin - therapeutic use; Colorectal cancer; Flow cytometry; Gastric cancer; Gene expression; Genetic translation; Humans; Inhibitors; Initiation factor eIF-5A; Leukemia; Lung cancer; Lung cancer, Non-small cell; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Membranes; MicroRNA; MicroRNAs; MicroRNAs - physiology; miRNA; Non-small cell lung carcinoma; Peptide Initiation Factors; Proteins; Reverse transcription; Ribonucleic acid; RNA; RNA-Binding Proteins; Sensitivity; Sensitivity analysis; Sensitivity enhancement; Target recognition; Viability
• ISSN: 2314-6133; 2314-6141
• DOI: 10.1155/2018/1769040

We determined the role of microRNA (miR)-9 in regulating cisplatin chemoresistance in nonsmall cell lung cancer (NSCLC) cells. miR-9 and eukaryotic translation initiation factor 5A2 (eIF5A2) levels were examined by reverse transcription–quantitative PCR. Cell Counting Kit-8 and the 5-ethynyl-2′-deoxyuridine (EdU) assay were used to determine the effects of miR-9 mimic or inhibitor on NSCLC cell proliferation and viability, respectively. Bioinformatics was used to analyze the relationship between miR-9 and eIF5A2. Flow cytometry was used to analyze the percentage of apoptotic cells. miR-9 mimic enhanced cisplatin sensitivity, while miR-9 inhibitor produced the opposite result. eIF5A2 was identified as a potential target of miR-9, where miR-9 regulated eIF5A2 expression at mRNA and protein level. miR-9 mimic decreased the expression of eIF5A2 mRNA and protein, while miR-9 inhibitor increased eIF5A2 expression. eIF5A2 knockdown resolved the effects of miR-9 mimic or inhibitor on cisplatin sensitivity. miR-9 may be a potential biomarker for enhancing cisplatin sensitivity by regulating eIF5A2 in NSCLC cells.